Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876121 | 0.85 | CA2 (0.66) | TP53CA2ATMALDH1A1CYP2C9 | |
| SCHEMBL3869026 | 0.73 | CYP2C9 (0.72) | TP53ATMALDH1A1CYP2C9MAPT | |
| SCHEMBL3874256 | 0.72 | CYP2C9 (0.57) | TP53ALDH1A1CYP2C9MAPTTSHR | |
| SCHEMBL15503867 | 0.67 | USP2 (0.78) | ALDH1A1CYP2C9MAPTTSHRNPSR1 | |
| SCHEMBL3870350 | 0.67 | LMNA (0.54) | TP53ALDH1A1CYP2C9MAPTTSHR | |
| SCHEMBL25482005 | 0.65 | TDP1 (0.70) | TP53ALDH1A1CYP2C9MAPTTSHR | |
| SCHEMBL25482090 | 0.65 | ALDH1A1 (0.74) | ALDH1A1MAPTTSHRNPSR1LMNA | |
| SCHEMBL4213820 | 0.65 | RAB9A (0.69) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL21586275 | 0.64 | PIK3C2A (0.64) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL30002936 | 0.64 | PIK3C2A (0.64) | ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | TP53 4525/4885CA2 138/4885ATM 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.